Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 2
2022 1
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Bedke J, Gakis G, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Garcia Del Muro X, Rodriguez-Vida A, Cicin I, Harputluoglu H, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Hamid O, Liepa AM, Wijayawardana S, Russo F, Walgren RA, Zimmermann AH, Hozak RR, Bell-McGuinn KM, Powles T; RANGE study investigators. Petrylak DP, et al. Lancet Oncol. 2020 Jan;21(1):105-120. doi: 10.1016/S1470-2045(19)30668-0. Epub 2019 Nov 18. Lancet Oncol. 2020. PMID: 31753727 Free PMC article. Clinical Trial.
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.
Wong SK, Blum SM, Sun X, Da Silva IP, Zubiri L, Ye F, Bai K, Zhang K, Ugurel S, Zimmer L, Livingstone E, Schadendorf D, Serra-Bellver P, Muñoz-Couselo E, Ortiz C, Lostes J, Huertas RM, Arance A, Pickering L, Long GV, Carlino MS, Buchbinder EI, Vázquez-Cortés L, Jara-Casas D, Márquez-Rodas I, González-Espinoza IR, Balko JM, Menzies AM, Sullivan RJ, Johnson DB. Wong SK, et al. Among authors: vazquez cortes l. Eur J Cancer. 2023 Mar;181:188-197. doi: 10.1016/j.ejca.2022.12.013. Epub 2022 Dec 27. Eur J Cancer. 2023. PMID: 36680880
Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma.
Rodríguez-Cid JR, Campos-Gomez S, García-Montes V, Magallanes-Maciel M, Flores-Mariñelarena RR, Fernández-Garibay VM, González-Espinoza IR, Ceja-García JP, Cázarez-Price JC, Martínez-Barrera L, Barriguete-Parra L, Zuloaga-Fernandez CJ, Kuri-Exsome R, Suárez-García D, Gonzalez-Villanueva JI, Flores-Anaya N, Acevedo-Delgado JA, Astorga-Ramos AM, Gerson-Cwilich R, Villalobos-Prieto A, Rodríguez-Silva C, Noriega-Iriondo MF, Vázquez-Cortés L, Perales-Rodríguez E, Acosta-Espinoza A, Perez-Lozano Y, Capdeville-García D, Alatorre-Alexander JA. Rodríguez-Cid JR, et al. Among authors: vazquez cortes l. JCO Glob Oncol. 2020 Mar;6:462-470. doi: 10.1200/JGO.19.00330. JCO Glob Oncol. 2020. PMID: 32196388 Free PMC article.